ArticleTurkish journal of biology = Turk biyoloji dergisi2026
Antiatopic dermatitis activity of
Article in Turkish journal of biology = Turk biyoloji dergisi, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/aim: Materials and methods: LFM was collected from snails fed long beans and melon rinds for 4 weeks, freeze-dried, and analyzed using liquid chromatography-mass spectrometry followed by network pharmacology (NP) analysis to identify its bioactive compounds. A total of 60 BALB/c mice were sensitized on the dorsal skin with 1% 2,4-dinitrochlorobenzene and subsequently treated with dexamethasone or LFM cream (5% or 10%), which was applied daily for 7 days. Skin samples were collected on days 0, 3, 5, and 7 for immunohistological analysis. Results: The results demonstrated that LFM contained 61 bioactive compounds, 16 of which interacted with seven target proteins: CCL2, TNF, PTGS2, SYK, MMP9, AKT1, and ICAM1. The NP analysis identified three major bioactive compounds in LFM-macamide, N-benzyloleamide, and a compound tentatively annotated as eplerenone-that potentially targeted CCL2 and TNF, which may serve as key regulators associated with the anti-AD effects of LFM. LFM 5% cream significantly reduced Atopic Dermatitis Severity Index (ADSI) scores and interleukin-1β (IL-1β) expression on day 5 (p < 0.05). LFM normalized epidermal thickness and increased the numbers of macrophages and mast cells (p < 0.05), suggesting a potential role in tissue remodeling and inflammation resolution during skin recovery. Conclusion: LFM demonstrated potential anti-AD effects by modulating CCL2- and TNF-associated pathways. LFM 5% cream reduced ADSI scores and IL-1β expression while normalizing epidermal thickness, potentially through immunomodulatory responses during the skin recovery phase.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.